Moleculin Biotech Announces Registered Direct Offering and Concurrent Private Placement
Houston, TX, February 25, 2025 – Moleculin Biotech, Inc. (NASDAQ: MBRX), a biotech company specializing in the development of drugs for hard-to-treat tumors and viruses, recently announced a securities purchase agreement with an institutional investor. This agreement pertains to a registered direct offering and a concurrent private placement, collectively referred to as the “Offering.”
Registered Direct Offering
Under the terms of the registered direct offering, the institutional investor will purchase 3,271,029 shares of common stock or pre-funded warrants in lieu thereof at a price of $1.07 per share.
Concurrent Private Placement
The concurrent private placement involves the issuance of warrants to purchase up to 6,542,058 shares of common stock. The warrants will have an exercise price of $1.07 per share and will become exercisable following the receipt of shareholder approval. These warrants will expire five years from the initial exercise date.
Impact on Moleculin Biotech
The Offering represents a significant capital infusion for Moleculin, which will enable the company to advance its clinical programs and continue its research efforts. The proceeds from the Offering are expected to be approximately $10 million, before deducting the placement agent fees and other estimated offering expenses.
Impact on the World
The successful completion of the Offering could have a positive impact on the biotech industry as a whole, as it demonstrates investor confidence in Moleculin’s innovative drug development pipeline. Additionally, the funds raised could potentially lead to the discovery and development of new treatments for various hard-to-treat tumors and viruses, ultimately benefiting patients and healthcare systems worldwide.
Conclusion
Moleculin Biotech’s announcement of the Offering represents an exciting development for the company and the biotech industry. With the proceeds from this capital raise, Moleculin can continue its mission to develop novel drugs for hard-to-treat diseases, potentially leading to significant advancements in healthcare. As a responsible investor, it is essential to monitor the progress of Moleculin’s clinical programs and stay informed about any updates regarding its drug development pipeline.
- Moleculin Biotech announces a registered direct offering and concurrent private placement.
- Institutional investor to purchase 3,271,029 shares or pre-funded warrants at $1.07 per share.
- Warrants to purchase up to 6,542,058 shares issued in a private placement.
- Proceeds from the Offering expected to be approximately $10 million.
- Capital infusion will support Moleculin’s clinical programs and research efforts.
- Positive impact on the biotech industry, potentially leading to new treatments for hard-to-treat diseases.
